Rhythm Pharmaceuticals (RYTM) to Acquire Global Rights to Oral MC4R Agonist LB54640 from LG Chem Life Sciences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation Rhythm to advance LB54640 in two Phase 2 clinical trials BOSTON, Jan. 04, 2024 Rhythm Pharmaceuticals,.
As per Future Market Insights’ latest industry analysis, the valuation for the global Anti-adhesion Barrier Gels Market is estimated to be around US$ 93.4 Million in 2022 and is projected to exhibit a CAGR growth of close to 8.4% over the forecast period, with an estimated valuation of US$ 209.8 Million in 2032.An a.